Page last updated: 2024-10-25

deferoxamine and Atrophy

deferoxamine has been researched along with Atrophy in 10 studies

Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.

Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.

Research Excerpts

ExcerptRelevanceReference
"Deferoxamine (DFX), a potent iron-chelating agent, reduces brain edema and neuronal cell injury that develop due to the hemolysis cascade."7.78Effects of statin and deferoxamine administration on neurological outcomes in a rat model of intracerebral hemorrhage. ( Chun, HJ; Hwang, SJ; Jwa, CS; Kim, DW; Kim, EH; Kim, YS; Lee, YK; Ryou, H; Yi, HJ, 2012)
"Deferoxamine (DFX) reduces brain edema, neurological deficits, and brain atrophy after intracerebral hemorrhage (ICH) in aged and young rats."7.76Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration. ( Hua, Y; Keep, RF; Morgenstern, LB; Okauchi, M; Schallert, T; Xi, G, 2010)
"Deferoxamine (DFX) reduces brain edema, neuronal death, and neurological deficits after intracerebral hemorrhage (ICH) in young rats."7.75Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. ( Hua, Y; Keep, RF; Morgenstern, LB; Okauchi, M; Xi, G, 2009)
"Deferoxamine (DFX), a potent iron-chelating agent, reduces brain edema and neuronal cell injury that develop due to the hemolysis cascade."3.78Effects of statin and deferoxamine administration on neurological outcomes in a rat model of intracerebral hemorrhage. ( Chun, HJ; Hwang, SJ; Jwa, CS; Kim, DW; Kim, EH; Kim, YS; Lee, YK; Ryou, H; Yi, HJ, 2012)
"Deferoxamine (DFX) reduces brain edema, neurological deficits, and brain atrophy after intracerebral hemorrhage (ICH) in aged and young rats."3.76Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration. ( Hua, Y; Keep, RF; Morgenstern, LB; Okauchi, M; Schallert, T; Xi, G, 2010)
"Deferoxamine (DFX) reduces brain edema, neuronal death, and neurological deficits after intracerebral hemorrhage (ICH) in young rats."3.75Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. ( Hua, Y; Keep, RF; Morgenstern, LB; Okauchi, M; Xi, G, 2009)
"Deferoxamine was used as an iron chelator."1.33Long-term effects of experimental intracerebral hemorrhage: the role of iron. ( Hoff, JT; Hua, Y; Keep, RF; Nakamura, T; Schallert, T; Wu, J; Xi, G, 2006)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (40.00)29.6817
2010's5 (50.00)24.3611
2020's1 (10.00)2.80

Authors

AuthorsStudies
Vinke, JSJ1
Gorter, AR1
Eisenga, MF1
Dam, WA1
van der Meer, P1
van den Born, J1
Bakker, SJL1
Hoes, MF1
de Borst, MH1
Jauregui, R1
Park, KS1
Bassuk, AG1
Mahajan, VB1
Tsang, SH1
Qin, Y1
Li, G1
Sun, Z1
Xu, X1
Gu, J1
Gao, F1
Okauchi, M2
Hua, Y3
Keep, RF3
Morgenstern, LB2
Xi, G3
Schallert, T2
Chun, HJ1
Kim, DW1
Yi, HJ1
Kim, YS1
Kim, EH1
Hwang, SJ1
Jwa, CS1
Lee, YK1
Ryou, H1
Zhang, L1
Hu, R1
Li, M1
Li, F1
Meng, H1
Zhu, G1
Lin, J1
Feng, H1
Arora, A1
Wren, S1
Gregory Evans, K1
Morad, Y1
Banin, E1
Averbukh, E1
Berenshtein, E1
Obolensky, A1
Chevion, M1
Nakamura, T1
Wu, J1
Hoff, JT1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Safety and Effectiveness Study of Deferoxamine and Xingnaojing Injection in Intracerebral Hemorrhage[NCT02367248]Phase 1/Phase 2180 participants (Anticipated)Interventional2015-03-31Recruiting
Futility Study of Deferoxamine in Intracerebral Hemorrhage[NCT01662895]Phase 242 participants (Actual)Interventional2013-03-18Terminated (stopped due to By DSMB on October 18, 2013 due to increased incidence of ARDS. See modified protocol [NCT02175225)
Study of Deferoxamine Mesylate in Intracerebral Hemorrhage[NCT02175225]Phase 2294 participants (Actual)Interventional2014-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Patients Who Died During the 90-day Study Period

Mortality at any time from randomization through day-90 (NCT01662895)
Timeframe: 90 days

InterventionParticipants (Count of Participants)
Deferoxamine3
Normal Saline0

Number of Patients With Hypotension

(NCT01662895)
Timeframe: within 7 days or discharge

InterventionParticipants (Count of Participants)
Deferoxamine1
Normal Saline1

Number of Patients With New Visual or Auditory Changes

(NCT01662895)
Timeframe: within 7 days or discharge

InterventionParticipants (Count of Participants)
Deferoxamine0
Normal Saline1

Number of Patients With Serious Adverse Events

(NCT01662895)
Timeframe: 90 days

InterventionParticipants (Count of Participants)
Deferoxamine9
Normal Saline6

Number of Subjects With Acute Respiratory Distress Syndrome

(NCT01662895)
Timeframe: 90 days

InterventionParticipants (Count of Participants)
Deferoxamine6
Normal Saline0

Number of Subjects With Allergic/Anaphylactic Reaction

(NCT01662895)
Timeframe: within 7 days or discharge

InterventionParticipants (Count of Participants)
Deferoxamine0
Normal Saline0

Number of Subjects With Modified Rankin Scale (mRS) Score 0-2

"The primary outcome measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 90 days.~The minimum mRS score is 0 (i.e. no disability). The maximum score is 6 (i.e. dead)." (NCT01662895)
Timeframe: 90 days

InterventionParticipants (Count of Participants)
Deferoxamine6
Normal Saline10

Number of Subjects With mRS Score 0-3

The proportion of DFO- and placebo-treated subjects with mRS 0-3 vs. 4-6 at 90 days (NCT01662895)
Timeframe: 90 days

InterventionParticipants (Count of Participants)
Deferoxamine12
Normal Saline14

Adverse Event of Special Interest: Number of Patients With Allergic Reactions (During Infusion of Study Drug)

Adverse event of special interest: anaphylaxis at any time during the study infusion (NCT02175225)
Timeframe: during the study infusion

InterventionParticipants (Count of Participants)
Deferoxamine Mesylate3
Normal Saline0

Adverse Event of Special Interest: Number of Patients With Hypotension

Hypotension requiring medical intervention at any time during the study infusion that could not be explained by other causes (NCT02175225)
Timeframe: during the study infusion

InterventionParticipants (Count of Participants)
Deferoxamine Mesylate1
Normal Saline2

Adverse Event of Special Interest: Number of Patients With New Visual or Auditory Changes

Adverse event of special interest: development of new and unexplained visual or auditory changes after initiation of the study infusion (NCT02175225)
Timeframe: after initiation of study infusion

InterventionParticipants (Count of Participants)
Deferoxamine Mesylate3
Normal Saline4

Number of Patients With Symptomatic Cerebral Edema

Edema accompanied by an unexplained increase of more than four points on the US National Institutes of Health Stroke Scale or a decrease of more than two points in Glasgow Coma Scale score during the first week after the intracerebral haemorrhage. (NCT02175225)
Timeframe: 7 days

InterventionParticipants (Count of Participants)
Deferoxamine Mesylate9
Normal Saline5

Number of Subjects Experiencing Serious Adverse Events

Number of subjects experiencing Serious adverse events at any time from randomization through day 90 (NCT02175225)
Timeframe: 90 days

InterventionParticipants (Count of Participants)
Deferoxamine Mesylate39
Normal Saline49

Number of Subjects With Serious Adverse Events Within 7 Days

Number of Subjects Experiencing Serious Adverse Events within 7 days of randomization (NCT02175225)
Timeframe: 7 days

InterventionParticipants (Count of Participants)
Deferoxamine Mesylate24
Normal Saline26

Proportion of Patients With Modified Rankin Scale (mRS) Score 0-2 at 180 Days

Another measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 180 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome. (NCT02175225)
Timeframe: 180 days

InterventionParticipants (Count of Participants)
Deferoxamine Mesylate61
Normal Saline48

Proportion of Patients With Modified Rankin Scale (mRS) Score 0-2 at 90 Days

The primary outcome measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 90 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome. (NCT02175225)
Timeframe: 90 days

InterventionParticipants (Count of Participants)
Deferoxamine Mesylate48
Normal Saline47

Proportion of Patients With Modified Rankin Scale (mRS) Score 0-3 at 180 Days

Another measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-3 at 180 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome. (NCT02175225)
Timeframe: 180 days

InterventionParticipants (Count of Participants)
Deferoxamine Mesylate97
Normal Saline92

Proportion of Patients With mRS Score 0-3 at 90 Days

"Another measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-3 at 90 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome.~Although mRS 0-3 is less favorable than the primary outcome of mRS 0-2, it would still be a desirable effect in patients with ICH given that no treatments exist to reduce disability." (NCT02175225)
Timeframe: 90 days

InterventionParticipants (Count of Participants)
Deferoxamine Mesylate91
Normal Saline82

Adverse Event of Special Interest: Number of Patients With Respiratory Compromise

Adverse event of special interest: Respiratory compromise of any cause, including acute respiratory distress syndrome, in hospital until day 7 or discharge [whichever was earlier] (NCT02175225)
Timeframe: 7 days

,
InterventionParticipants (Count of Participants)
All causeCause by acute respiratory distress syndrome
Deferoxamine Mesylate202
Normal Saline231

Proportion of Subjects With Good Outcome (mRS 0-2) in the Early vs. Delayed Treatment Time Windows

Analyses will be expanded to include an interaction between treatment and OTT window and the magnitude of the treatment effect, and corresponding confidence interval, will be estimated for each time window (<12 hours vs. >/= 12 hours) in order to explore the presence of a differential treatment effect in the OTT windows. (NCT02175225)
Timeframe: 90 days

,
InterventionParticipants (Count of Participants)
Onset to treatment time <=12 hoursOnset to treatment time >12 hours
Deferoxamine Mesylate1533
Normal Saline1928

Other Studies

10 other studies available for deferoxamine and Atrophy

ArticleYear
Iron deficiency is related to lower muscle mass in community-dwelling individuals and impairs myoblast proliferation.
    Journal of cachexia, sarcopenia and muscle, 2023, Volume: 14, Issue:4

    Topics: Adult; Animals; Atrophy; Cell Proliferation; Deferoxamine; Female; Ferritins; Humans; Independent Li

2023
Deferoxamine-induced electronegative ERG responses.
    Documenta ophthalmologica. Advances in ophthalmology, 2018, Volume: 137, Issue:1

    Topics: Atrophy; Deferoxamine; Electroretinography; Fluorescein Angiography; Humans; Iron Overload; Male; Mi

2018
Comparison of the effects of nimodipine and deferoxamine on brain injury in rat with subarachnoid hemorrhage.
    Behavioural brain research, 2019, 07-23, Volume: 367

    Topics: Animals; Atrophy; Cognitive Dysfunction; Deferoxamine; Disease Models, Animal; Ferritins; Male; Maze

2019
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats.
    Stroke, 2009, Volume: 40, Issue:5

    Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases;

2009
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats.
    Stroke, 2009, Volume: 40, Issue:5

    Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases;

2009
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats.
    Stroke, 2009, Volume: 40, Issue:5

    Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases;

2009
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats.
    Stroke, 2009, Volume: 40, Issue:5

    Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases;

2009
Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration.
    Stroke, 2010, Volume: 41, Issue:2

    Topics: Aging; Animals; Atrophy; Brain Edema; Caudate Nucleus; Cerebral Hemorrhage; Deferoxamine; Disease Mo

2010
Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration.
    Stroke, 2010, Volume: 41, Issue:2

    Topics: Aging; Animals; Atrophy; Brain Edema; Caudate Nucleus; Cerebral Hemorrhage; Deferoxamine; Disease Mo

2010
Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration.
    Stroke, 2010, Volume: 41, Issue:2

    Topics: Aging; Animals; Atrophy; Brain Edema; Caudate Nucleus; Cerebral Hemorrhage; Deferoxamine; Disease Mo

2010
Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration.
    Stroke, 2010, Volume: 41, Issue:2

    Topics: Aging; Animals; Atrophy; Brain Edema; Caudate Nucleus; Cerebral Hemorrhage; Deferoxamine; Disease Mo

2010
Effects of statin and deferoxamine administration on neurological outcomes in a rat model of intracerebral hemorrhage.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2012, Volume: 33, Issue:2

    Topics: Analysis of Variance; Animals; Atrophy; Brain Edema; CD11b Antigen; Cerebral Hemorrhage; Deferoxamin

2012
Deferoxamine attenuates iron-induced long-term neurotoxicity in rats with traumatic brain injury.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2013, Volume: 34, Issue:5

    Topics: Analysis of Variance; Animals; Apoferritins; Atrophy; Brain; Brain Injuries; Deferoxamine; Disease M

2013
Desferrioxamine related maculopathy: a case report.
    American journal of hematology, 2004, Volume: 76, Issue:4

    Topics: Aged; Aged, 80 and over; Atrophy; Deferoxamine; Diagnosis, Differential; Female; Glaucoma, Open-Angl

2004
Treatment of ocular tissues exposed to nitrogen mustard: beneficial effect of zinc desferrioxamine combined with steroids.
    Investigative ophthalmology & visual science, 2005, Volume: 46, Issue:5

    Topics: Animals; Atrophy; Burns, Chemical; Chemical Warfare Agents; Corneal Diseases; Corneal Neovasculariza

2005
Long-term effects of experimental intracerebral hemorrhage: the role of iron.
    Journal of neurosurgery, 2006, Volume: 104, Issue:2

    Topics: Animals; Atrophy; Behavior, Animal; Brain; Deferoxamine; Ferritins; Intracranial Hemorrhages; Iron;

2006